Cargando…

Nanomedicines for the management of diabetic nephropathy: present progress and prospects

Diabetic nephropathy (DN) is a serious microvascular consequence of diabetes mellitus (DM), posing an encumbrance to public health worldwide. Control over the onset and progress of DN depend heavily on early detection and effective treatment. DN is a major contributor to end-stage renal disease, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Paul, Paramita, Chacko, Leena, Dua, Tarun K., Chakraborty, Pratik, Paul, Udita, Phulchand, Vishwakarma Vishal, Jha, Niraj K., Jha, Saurabh K., Kandimalla, Ramesh, Dewanjee, Saikat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10656621/
https://www.ncbi.nlm.nih.gov/pubmed/38027185
http://dx.doi.org/10.3389/fendo.2023.1236686
_version_ 1785137045205680128
author Paul, Paramita
Chacko, Leena
Dua, Tarun K.
Chakraborty, Pratik
Paul, Udita
Phulchand, Vishwakarma Vishal
Jha, Niraj K.
Jha, Saurabh K.
Kandimalla, Ramesh
Dewanjee, Saikat
author_facet Paul, Paramita
Chacko, Leena
Dua, Tarun K.
Chakraborty, Pratik
Paul, Udita
Phulchand, Vishwakarma Vishal
Jha, Niraj K.
Jha, Saurabh K.
Kandimalla, Ramesh
Dewanjee, Saikat
author_sort Paul, Paramita
collection PubMed
description Diabetic nephropathy (DN) is a serious microvascular consequence of diabetes mellitus (DM), posing an encumbrance to public health worldwide. Control over the onset and progress of DN depend heavily on early detection and effective treatment. DN is a major contributor to end-stage renal disease, and a complete cure is yet to be achieved with currently available options. Though some therapeutic molecules have exhibited promise in treating DN complications, their poor solubility profile, low bioavailability, poor permeation, high therapeutic dose and associated toxicity, and low patient compliance apprehend their clinical usefulness. Recent research has indicated nano-systems as potential theranostic platforms displaying futuristic promise in the diagnosis and treatment of DN. Early and accurate diagnosis, site-specific delivery and retention by virtue of ligand conjugation, and improved pharmacokinetic profile are amongst the major advantages of nano-platforms, defining their superiority. Thus, the emergence of nanoparticles has offered fresh approaches to the possible diagnostic and therapeutic strategies regarding DN. The present review corroborates an updated overview of different types of nanocarriers regarding potential approaches for the diagnosis and therapy of DN.
format Online
Article
Text
id pubmed-10656621
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-106566212023-01-01 Nanomedicines for the management of diabetic nephropathy: present progress and prospects Paul, Paramita Chacko, Leena Dua, Tarun K. Chakraborty, Pratik Paul, Udita Phulchand, Vishwakarma Vishal Jha, Niraj K. Jha, Saurabh K. Kandimalla, Ramesh Dewanjee, Saikat Front Endocrinol (Lausanne) Endocrinology Diabetic nephropathy (DN) is a serious microvascular consequence of diabetes mellitus (DM), posing an encumbrance to public health worldwide. Control over the onset and progress of DN depend heavily on early detection and effective treatment. DN is a major contributor to end-stage renal disease, and a complete cure is yet to be achieved with currently available options. Though some therapeutic molecules have exhibited promise in treating DN complications, their poor solubility profile, low bioavailability, poor permeation, high therapeutic dose and associated toxicity, and low patient compliance apprehend their clinical usefulness. Recent research has indicated nano-systems as potential theranostic platforms displaying futuristic promise in the diagnosis and treatment of DN. Early and accurate diagnosis, site-specific delivery and retention by virtue of ligand conjugation, and improved pharmacokinetic profile are amongst the major advantages of nano-platforms, defining their superiority. Thus, the emergence of nanoparticles has offered fresh approaches to the possible diagnostic and therapeutic strategies regarding DN. The present review corroborates an updated overview of different types of nanocarriers regarding potential approaches for the diagnosis and therapy of DN. Frontiers Media S.A. 2023-11-03 /pmc/articles/PMC10656621/ /pubmed/38027185 http://dx.doi.org/10.3389/fendo.2023.1236686 Text en Copyright © 2023 Paul, Chacko, Dua, Chakraborty, Paul, Phulchand, Jha, Jha, Kandimalla and Dewanjee https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Paul, Paramita
Chacko, Leena
Dua, Tarun K.
Chakraborty, Pratik
Paul, Udita
Phulchand, Vishwakarma Vishal
Jha, Niraj K.
Jha, Saurabh K.
Kandimalla, Ramesh
Dewanjee, Saikat
Nanomedicines for the management of diabetic nephropathy: present progress and prospects
title Nanomedicines for the management of diabetic nephropathy: present progress and prospects
title_full Nanomedicines for the management of diabetic nephropathy: present progress and prospects
title_fullStr Nanomedicines for the management of diabetic nephropathy: present progress and prospects
title_full_unstemmed Nanomedicines for the management of diabetic nephropathy: present progress and prospects
title_short Nanomedicines for the management of diabetic nephropathy: present progress and prospects
title_sort nanomedicines for the management of diabetic nephropathy: present progress and prospects
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10656621/
https://www.ncbi.nlm.nih.gov/pubmed/38027185
http://dx.doi.org/10.3389/fendo.2023.1236686
work_keys_str_mv AT paulparamita nanomedicinesforthemanagementofdiabeticnephropathypresentprogressandprospects
AT chackoleena nanomedicinesforthemanagementofdiabeticnephropathypresentprogressandprospects
AT duatarunk nanomedicinesforthemanagementofdiabeticnephropathypresentprogressandprospects
AT chakrabortypratik nanomedicinesforthemanagementofdiabeticnephropathypresentprogressandprospects
AT pauludita nanomedicinesforthemanagementofdiabeticnephropathypresentprogressandprospects
AT phulchandvishwakarmavishal nanomedicinesforthemanagementofdiabeticnephropathypresentprogressandprospects
AT jhanirajk nanomedicinesforthemanagementofdiabeticnephropathypresentprogressandprospects
AT jhasaurabhk nanomedicinesforthemanagementofdiabeticnephropathypresentprogressandprospects
AT kandimallaramesh nanomedicinesforthemanagementofdiabeticnephropathypresentprogressandprospects
AT dewanjeesaikat nanomedicinesforthemanagementofdiabeticnephropathypresentprogressandprospects